Ronald E. Blaylock elected to Pfizer's Board of Directors

PfizerPfizer Inc. has announced the election of Ronald E. Blaylock to its Board of Directors, effective immediately. Mr. Blaylock was also appointed to the Corporate Governance and Science and Technology Committees of Pfizer's Board.

Mr. Blaylock, 57, is the Founder, Managing Partner of GenNx360 Capital Partners, a private equity firm focused on investing in industrial and business services companies in the U.S. middle market, since 2006. Prior to launching GenNx360 Capital Partners, Mr. Blaylock founded and managed Blaylock & Company, an investment banking firm. He has also held senior management positions at UBS, PaineWebber Group, and Citicorp.

Mr. Blaylock also serves as a Director of CarMax, Inc., Radio One, Inc. and W.R. Berkley, Inc., as well as a Director of Syncreon U.S., a for-profit private company. He is a member of the Board of Trustees of Carnegie Hall, the Board of Overseers of New York University Stern School of Business, and the Board of Trustees of Prep for Prep, a not-for-profit organization. Mr. Blaylock was voted Capital Raiser of the Year by Corporate Finance Magazine in 1999, and was named one of the Most Powerful Blacks on Wall Street by Black Enterprise Magazine in 2005, and Man of the Year by Covenant House.

"We are pleased to welcome Ron Blaylock to Pfizer's Board of Directors. He brings business, financial and leadership expertise, which will be an asset to Pfizer's diverse Board and to our company," stated Ian Read, Pfizer's Chairman and Chief Executive Officer. "The addition of Ron to our Board helps ensure that Pfizer continues to benefit from a breadth and variety of experience."

About Pfizer Inc.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Most Popular Now

FDA awards 15 grants for clinical trials to stimul…

The U.S. Food and Drug Administration today announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to...

A need for bananas? Dietary potassium regulates ca…

Bananas and avocados - foods that are rich in potassium - may help protect against pathogenic vascular calcification, also known as hardening of the arteries. University ...

Amgen and CytomX Therapeutics announce strategic c…

Amgen (NASDAQ:AMGN) and CytomX Therapeutics, Inc., (NASDAQ:CTMX) today announced that the companies have entered into a strategic collaboration in immuno-oncology. The co...

Roche launches NAVIFY Tumor Board solution to prov…

Roche (SIX: RO, ROG; OTCQX:RHHBY), has announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-...

Tagrisso granted breakthrough therapy designation …

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatm...

Pfizer launches novel programs to put important su…

Pfizer today unveils enhanced offerings to help patients manage their life with cancer. Pfizer Oncology Together is a first-of-its-kind program for patients taking Pfizer...

Novartis and UC Berkeley collaborate to tackle 'un…

Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pu...

Printed meds could reinvent pharmacies, drug resea…

A technology that can print pure, ultra-precise doses of drugs onto a wide variety of surfaces could one day enable on-site printing of custom-dosed medications at pharma...

Amgen and Simcere announce strategic collaboration…

Amgen (NASDAQ: AMGN) and Simcere Pharmaceutical Group have announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. Th...

IDF and Novo Nordisk launch first-ever global surv…

To mark World Heart Day today, the International Diabetes Federation (IDF) has partnered with Novo Nordisk to launch the first-ever multi-country online survey investigat...

FDA awards six grants for natural history studies …

The U.S. Food and Drug Administration today announced it has awarded six new research grants for natural history studies in rare diseases. The aim of the research is to i...

Indian government needs to do more to tackle risin…

In India, the sale of antibiotics requiring the tightest control and regulation is rising the fastest, according to an analysis by researchers at Queen Mary University of...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]